Consistent with this concept, recent work has demonstrated metabolism-directed strategies to overcome EGFR-TKI resistance, including inhibition of BCAT1/BCAA metabolism and disruption of kynurenine–AHR signaling in the tumor microenvironment [39], [40]. This evidence concerns the gene BCAT1 and neoplasm.